

ASX ANNOUNCEMENT

10 November 2020

Anti-calcification comparison study shows positive interim results

Brisbane, Australia and Minneapolis USA, - Anteris Technologies Ltd (ASX: AVR) (**Anteris or the Company**), reports interim results from the Company's anti-calcification study indicating its ADAPT[®] treated tissue has superior anti-calcification attributes compared with tissues used in competitor valves.

Results at the half-way point (four months) showed the ADAPT[®] treated tissue – used in the DurAVR[™] 3D single-piece aortic valve – had approximately 40% less calcium concentration compared with the Medtronic AOA[™] arm – tissue used in commercially available SAVR (surgical aortic valve replacement) and TAVR (transcatheter aortic valve replacement) valves.

“The results were highly positive for ADAPT[®], indicating our ADAPT[®] anti-calcification treatment is statistically superior to both of the major competitors,” Anteris Chief Executive Officer, Mr Wayne Paterson, said.

In the study (begun in May 2020, <https://bit.ly/2U43nbM>), 48 juvenile rats were implanted with four different samples into separate subcutaneous pockets for calcification evaluation of the following tissues:

- ADAPT[®]-treated bovine pericardium
- AOA[™]-treated porcine tissue
- AOA[™]-treated bovine tissue
- Control (Glutaraldehyde-treated bovine pericardium)

The interim results correlated with existing clinical data and those of the prior head-to-head study with a similar protocol which produced significant differentials between ADAPT[®] tissue and Edwards Life Sciences' Thermafix tissue at the eight to 12-month mark.

Calcification (hardening) is a significant contributor to the failure of heart valve replacements made from animal tissue. There is an imperative for better anti-calcification treatments such as ADAPT[®] to help ensure replacement heart valves last longer and work better.

The final results of the eight month study will be used in the US Food and Drug Administration submissions to demonstrate DurAVR[™] superiority compared with currently available valves subject to the final results being consistent with these positive interim results.

“Whilst we have long understood the clinical superiority of ADAPT[®], it's critical for the regulatory submission to prove this against market incumbents specifically in the TAVR space,” Mr Paterson said.

ENDS

Anteris Technologies Ltd

Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service:

T +61 1300 550 310 F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



For personal use only

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with the unique 3D single piece aortic valve design of DurAVR™, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Ms Kyahn Williamson
WE Communications
E: WE-AUAnterisTech@we-worldwide.com
P: +61 401 018 828

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech